Tolerogenic vaccines for multiple sclerosis
Author
Mannie, Mark D.; Curtis, Alan D. II
Abstract
Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.
Date
2013-01-28
Citation:
APA:
Mannie, Mark D., & Curtis, Alan D. II. (January 2013).
Tolerogenic vaccines for multiple sclerosis.
Hum Vaccin Immunother,
(9:5), p.1032–1038. Retrieved from
http://hdl.handle.net/10342/7818
MLA:
Mannie, Mark D., and Curtis, Alan D. II.
"Tolerogenic vaccines for multiple sclerosis". Hum Vaccin Immunother.
9:5. (1032–1038.),
January 2013.
February 24, 2021.
http://hdl.handle.net/10342/7818.
Chicago:
Mannie, Mark D. and Curtis, Alan D. II,
"Tolerogenic vaccines for multiple sclerosis," Hum Vaccin Immunother 9, no.
5 (January 2013),
http://hdl.handle.net/10342/7818 (accessed
February 24, 2021).
AMA:
Mannie, Mark D., Curtis, Alan D. II.
Tolerogenic vaccines for multiple sclerosis. Hum Vaccin Immunother.
January 2013;
9(5)
1032–1038. http://hdl.handle.net/10342/7818. Accessed
February 24, 2021.
Collections